PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Phase 2 Unknown 30 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multicenter, open label Phase II Clinical Trial. 30 advanced poorly differentiated thyroid carcinoma patients who were histopathologically confirmed inoperable were enrolled in this study.

Timeline

Start: 2017-03-06
Primary completion: 2018-12-31
Completion: 2019-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	75 mg/m2	Other
Subject	PLD	Unknown	35 mg/m2	Intravenous

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Summary

Timeline

Drugs

Indications